This company listing is no longer active
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Medlab Clinical Résultats passés
Passé contrôle des critères 0/6
Medlab Clinical's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 19.6% annually. Revenues have been declining at an average rate of 19.2% per year.
Informations clés
-18.9%
Taux de croissance des bénéfices
-7.9%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 9.6% |
| Taux de croissance des recettes | -19.2% |
| Rendement des fonds propres | -108.3% |
| Marge nette | -541.7% |
| Dernière mise à jour des bénéfices | 30 Jun 2022 |
Mises à jour récentes des performances passées
Recent updates
Shareholders May Be More Conservative With Medlab Clinical Limited's (ASX:MDC) CEO Compensation For Now
Oct 06
Is Medlab Clinical (ASX:MDC) In A Good Position To Invest In Growth?
Oct 05What We Learned About Medlab Clinical's (ASX:MDC) CEO Pay
Feb 21Medlab Clinical (ASX:MDC) Share Prices Have Dropped 69% In The Last Three Years
Dec 30
Medlab Clinical Limited (ASX:MDC) Is Expected To Breakeven In The Near Future
Nov 22Ventilation des recettes et des dépenses
Comment Medlab Clinical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -8 | 12 | 2 |
| 31 Mar 22 | 1 | -9 | 9 | 1 |
| 31 Dec 21 | 4 | -12 | 11 | 1 |
| 30 Sep 21 | 4 | -12 | 11 | 2 |
| 30 Jun 21 | 1 | -10 | 11 | 2 |
| 31 Mar 21 | 1 | -10 | 10 | 2 |
| 31 Dec 20 | 1 | -11 | 9 | 2 |
| 30 Sep 20 | 2 | -12 | 9 | 2 |
| 30 Jun 20 | 3 | -13 | 10 | 2 |
| 31 Mar 20 | 4 | -12 | 10 | 2 |
| 31 Dec 19 | 4 | -12 | 11 | 2 |
| 30 Sep 19 | 5 | -10 | 10 | 1 |
| 30 Jun 19 | 5 | -8 | 10 | 1 |
| 31 Mar 19 | 5 | -7 | 8 | 1 |
| 31 Dec 18 | 5 | -6 | 7 | 0 |
| 30 Sep 18 | 4 | -5 | 7 | 0 |
| 30 Jun 18 | 4 | -5 | 6 | 0 |
| 31 Mar 18 | 4 | -4 | 6 | 0 |
| 31 Dec 17 | 5 | -4 | 6 | 0 |
| 30 Sep 17 | 5 | -4 | 5 | 0 |
| 30 Jun 17 | 4 | -4 | 5 | 0 |
| 31 Mar 17 | 4 | -4 | 5 | 0 |
| 31 Dec 16 | 4 | -4 | 4 | 0 |
| 30 Sep 16 | 3 | -4 | 4 | 0 |
| 30 Jun 16 | 3 | -3 | 4 | 0 |
Des revenus de qualité: MDC is currently unprofitable.
Augmentation de la marge bénéficiaire: MDC is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: MDC is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accélération de la croissance: Unable to compare MDC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: MDC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.2%).
Rendement des fonds propres
ROE élevé: MDC has a negative Return on Equity (-108.25%), as it is currently unprofitable.